The biopharmaceutical company reported ($0.02) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.06) by $0.04.
Shares of Geron Corporation (GERN) traded down $0.01 during trading hours on Friday, hitting $2.06. The company had revenue of $0.16 million during the quarter, compared to analysts' expectations of $0.40 million. Geron Corporation's P/E ratio is N/A and the market value is 281.84M. The volume of FRED witnessed a shift from 2.9 million shares, based on a 50-day average, to 0.93 million shares. Geron Corp.'s revenue for the quarter was down 85.6% compared to the same quarter previous year. Where the relative strength index (RSI) is a technical momentum indicator that compares the magnitude of recent gains to recent losses in an attempt to determine excess buying & selling conditions of an asset, it is one of the most popular technical indicators, computed on the basis of the speed and direction of a stock's price movement.
GERN has been the topic of a number of other reports. Analysts have a mean recommendation of 2.70 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). BTIG Research reaffirmed a "neutral" rating on shares of Geron Corp.in a research note on Tuesday, September 20th. Geron Corporation presently has an average rating of "Hold" and a consensus target price of $3.75.
TRADEMARK VIOLATION NOTICE: "Stifel Nicolaus Reiterates "Hold" Rating for Geron Corporation (NASDAQ:GERN)" was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and global copyright and trademark law. The original version of this article can be read at https://weekherald.com/2017/11/13/geron-corporations-gern-hold-rating-reaffirmed-at-needham-company-llc.html. Parametric Portfolio Associates LLC raised its stake in shares of Geron Corporation by 59.4% in the second quarter. American International Group Inc grew its stake by buying 7,454 shares an increase of 8.1% in the quarter. BlackRock Investment Management LLC boosted its stake in Geron Corp.by 4.0% in the second quarter. Citigroup Inc now owns 4,900 shares valued at $11,000.
A few notable investment firms have updated their holdings. BlackRock Investment Management LLC now owns 590,291 shares of the biopharmaceutical company's stock valued at $1,582,000 after buying an additional 22,485 shares in the last quarter. The value of the company's investment in Geron Corporation went from $97,282,000 to $3,172,000 a change of $94,110,000 since the last quarter. Tudor Investment Corp ET AL now owns 52,369 shares of the biopharmaceutical company's stock worth $119,000 after acquiring an additional 5,669 shares in the last quarter. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.